Quite possible!
Were they depressive, because they did not receive gender-affirming hormone therapy? This study does not reveal.
This study also focused only on "moderate-to-severe depressive symptoms". What about other or lesser depressive symptoms?
"Gender-affirming hormone therapy was associated with lower rates of moderate-to-severe depressive symptoms among 3,592 trans and nonbinary people prescribed the treatment compared to those who didn’t receive the treatment, finds a study spanning 48 months of follow-up. JAMA Network Open"
From the key points and abstract:
"Key Points
Question
Is gender-affirming hormone therapy (GAHT) associated with lower rates of moderate to severe depressive symptoms in transgender, nonbinary, and gender diverse (TGD) adults in primary care?
Findings
In this cohort study of 3592 TGD patients in primary care at federally qualified community health centers in Boston and New York, 15.3% had moderate-to-severe depressive symptoms assessed using the Patient Health Questionnaire (PHQ). In addition, GAHT was associated with a lower risk of moderate-to-severe depressive symptoms across 48 months of follow-up.
Meaning
The findings of this study suggest that integrated GAHT with primary care and low-barrier GAHT access is associated with lower rates of mental health morbidity in TGD patients.
Abstract
Importance In the US, transgender, nonbinary, and gender diverse (TGD) adults have high rates of depression. Gender-affirming hormone therapy (GAHT) is associated with improved mental health outcomes, yet existing US studies have short follow ups and lack sample diversity.
Objective
To evaluate the use of GAHT delivered in primary care as an intervention for moderate-to-severe depressive symptoms in diverse TGD adult patients.
Design, Setting, and Participants
LEGACY was an observational cohort study conducted in federally qualified community health centers in Boston and New York that followed up TGD patients (N = 3592) from calendar years 2016 to 2019 (48 months). Participants included individuals aged 18 years or older, gender identity different from sex at birth, a past 12-month medical visit, and signed patient consent form in the electronic health record (EHR).
Exposures
Prescriptions for GAHT obtained from EHR data, using the date of the first and last GAHT prescription in each calendar year of observation (GAHT within the year vs no GAHT during the year).
Main Outcomes and Measures
...
Results
The median age of the 3592 patients was 28 (IQR, 24-36) years. ... In addition, 18.9% were nonbinary, 52.1% lived below the federal poverty level, 34.2% were publicly insured, 4.1% were uninsured, and 5.1% were living with HIV. At baseline, 84.5% of the individuals were prescribed GAHT and 15.3% reported moderate-to-severe depressive symptoms. ...
Conclusions and Relevance
In this longitudinal observational cohort study, GAHT was associated with lower rates of moderate-to-severe depressive symptoms, highlighting the importance of gender-affirming primary care models for TGD patients."
No comments:
Post a Comment